JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.4
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 14, Issue 4 (2022)
Iran J War Public Health 2022, 14(4): 385-390 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2022/08/1 | Accepted: 2022/10/13 | Published: 2022/11/1
Received: 2022/08/1 | Accepted: 2022/10/13 | Published: 2022/11/1
How to cite this article
Abbas A, Kata F. Relationship between Some Physiological Biomarkers in Obese Men and the Risk of Metabolic Syndrome. Iran J War Public Health 2022; 14 (4) :385-390
URL: http://ijwph.ir/article-1-1251-en.html
URL: http://ijwph.ir/article-1-1251-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
A.J. Abbas *1, F.S. Kata1
1- Department of Biology, College of Education for Pure Science, University of Basrah, Basrah, Iraq
Abstract (803 Views)
Aims: Obesity is associated with many diseases. Fat cells secrete biologically active substances known as biomarkers. This study aimed to assess the concentration of some biomarkers and take them as predictors of metabolic syndrome.
Instrument & Methods: In the present, 88 blood serum samples were collected from male volunteers who have metabolic health in Basra Province, Iraq. 28 samples were taken from men with normal weight, and 60 samples from obese men. 5mm of venous blood was taken from each donor, and the concentration of biomarkers including paraoxonase enzyme-1, plasminogen activator inhibitor-1, oxidized low-density lipoprotein and endothelin-1 were measured. Then, the effect of BMI and waist circumferences on the concentration of biomarkers was investigated.
Findings: A significant decrease in paraoxonase-1 concentration was observed in the obese group (p≤0.01), while plasminogen activator inhibitor-1 was significantly higher in the obese group compared to the normal weight group. There was no significant difference in the concentration of oxidized low-density lipoprotein and endothelin-1 between the two groups. There was a significant increase in the levels of plasminogen activator inhibitor-1 and endothelin-1 in the group with BMI>40 compared to the group with 40≥BMI≥35. There was no significant difference in the concentration of all biomarkers between the two waist circumference groups.
Conclusion: Obesity is a major cause of the metabolic syndrome, and abnormal levels of paraoxonase-1 and plasminogen activator inhibitor-1 associated with obesity are early warning signs of metabolic syndrome.
Instrument & Methods: In the present, 88 blood serum samples were collected from male volunteers who have metabolic health in Basra Province, Iraq. 28 samples were taken from men with normal weight, and 60 samples from obese men. 5mm of venous blood was taken from each donor, and the concentration of biomarkers including paraoxonase enzyme-1, plasminogen activator inhibitor-1, oxidized low-density lipoprotein and endothelin-1 were measured. Then, the effect of BMI and waist circumferences on the concentration of biomarkers was investigated.
Findings: A significant decrease in paraoxonase-1 concentration was observed in the obese group (p≤0.01), while plasminogen activator inhibitor-1 was significantly higher in the obese group compared to the normal weight group. There was no significant difference in the concentration of oxidized low-density lipoprotein and endothelin-1 between the two groups. There was a significant increase in the levels of plasminogen activator inhibitor-1 and endothelin-1 in the group with BMI>40 compared to the group with 40≥BMI≥35. There was no significant difference in the concentration of all biomarkers between the two waist circumference groups.
Conclusion: Obesity is a major cause of the metabolic syndrome, and abnormal levels of paraoxonase-1 and plasminogen activator inhibitor-1 associated with obesity are early warning signs of metabolic syndrome.
Keywords:
References
1. World Health organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation [Internet]. Geneva: World Health organization; 2000 [cited 2022, 13 Apr]. Available from: https://apps.who.int/iris/handle/10665/42330 [Link]
2. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88. [Link] [DOI:10.1186/1471-2458-9-88]
3. Son WM, Kim DY, Kim YS, Ha MS. Effect of obesity on blood pressure and arterial stiffness in middle-aged Korean women. Osong Public Health Res Perspect. 2017;8(6):369-72. [Link] [DOI:10.24171/j.phrp.2017.8.6.02]
4. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010;1212(1):E1-19. [Link] [DOI:10.1111/j.1749-6632.2010.05875.x]
5. Kata F, Alsulaitti SW, Adlan MM. Leptin and vascular cell adhesion protein 1 as physiological biomarkers in serum of women suffering from rheumatoid arthritis. Open Access Macedonian J Med Sci. 2022;10(A):164-9. [Link] [DOI:10.3889/oamjms.2022.8208]
6. Kota SK, Meher LK, Kota SK, Jammula S, Krishna SVS, Modi KD. Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian J Endocrinol Metab. 2013;17(3):402-12. [Link] [DOI:10.4103/2230-8210.111618]
7. Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON-1): a brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag gement. 2018;14:137-43. [Link] [DOI:10.2147/VHRM.S165173]
8. Mackness M, Sozmen EY. A critical review on human serum Paraoxonase-1 in the literature: truths and misconceptions. Turkish J Biochemist. 2021;46(1):3-8. [Link] [DOI:10.1515/tjb-2020-0186]
9. Aharoni S, Aviram M, Fuhrman B. Paraoxonase 1 (PON1) reduces macrophage inflammatory responses. Atherosclerosis. 2013;228(2):353-61. [Link] [DOI:10.1016/j.atherosclerosis.2013.03.005]
10. Sentí M, Tomás M, Fitó M, Weinbrenner T, Covas MI, Masiá R, et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab. 2003;88(11):5422-6. [Link] [DOI:10.1210/jc.2003-030648]
11. Staňková B, Vávrová L, Rychlíková J, Žák A. Changes in Paraoxonase 1 activity and concentration of conjugated dienes in connection with number of metabolic syndrome components. Klin Biochem Metabo. 2016;24(2):88-93. [Link]
12. Yildiz Y, Ozaksit G, Unlu BS, Ozgu E, Energin H, Kaba M, et al. Serum adiponectin level and clinical, metabolic, and hormonal markers in patients with polycystic ovary syndrome. Int J Fertil Steril. 2014;7(4):331-6. [Link]
13. Jung RG, Motazedian P, Ramirez FD, Simard T, Di Santo P, Visintini S, et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb J. 2018;16(1):12. [Link] [DOI:10.1186/s12959-018-0166-4]
14. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Yusuf S. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003;108(4):420-5. [Link] [DOI:10.1161/01.CIR.0000080884.27358.49]
15. Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipoprotein. Methods Mol Biol. 2010;610:403-17. [Link] [DOI:10.1007/978-1-60327-029-8_24]
16. Jallod AAR, Kata FS. Estimation of adiponectin hormone and antioxidants levels in type 2 diabetic patients in Dhiqar Province. J Global Pharma Technol. 2019;11(07):885-93. [Link]
17. Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, et al. Overview of OxLDL and its impact on cardiovascular health: focus on atherosclerosis. Front Pharmacol. 2021;11:613780. [Link] [DOI:10.3389/fphar.2020.613780]
18. Rani V, Deep G, Singh RK, Palle K, Yadav UC. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci. 2016;148:183-93. [Link] [DOI:10.1016/j.lfs.2016.02.002]
19. Pohjantähti-Maaroos H, Palomäki A, Kankkunen P, Laitinen R, Husgafvel S, Oksanen K. Circulating oxidized low-density lipoproteins and arterial elasticity: comparison between men with metabolic syndrome and physically active counterparts. Cardiovasc Diabetol. 2010;9(1):41. [Link] [DOI:10.1186/1475-2840-9-41]
20. Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp. 2015;63(1):41-52. [Link] [DOI:10.1007/s00005-014-0310-1]
21. van Harmelen V, Eriksson A, Astrom G, Wahlen K, Naslund E, Karpe F, et al. Vascular peptide endothelin-1 links fat accumulation with alterations of visceral adipocyte lipolysis. Diabetes. 2008;57(2):378-86. [Link] [DOI:10.2337/db07-0893]
22. Vanhoutte PM, Shimokawa H, Feletou M, Tang EHC. Endothelial dysfunction and vascular disease-a 30th anniversary update. Acta Physiol. 2017;219(1):22-96. [Link] [DOI:10.1111/apha.12646]
23. Ferretti G, Bacchetti T, Masciangelo S, Grugni G, Bicchiega V. Altered inflammation, paraoxonase-1 activity and HDL physicochemical properties in obese humans with and without Prader-Willi syndrome. Dis Model Mech. 2012;5(5):698-705. [Link] [DOI:10.1242/dmm.009209]
24. Krzystek-Korpacka M, Patryn E, Hotowy K, Czapińska E, Majda J, Kustrzeba-Wójcicka I, et al. Paraoxonase-1 activity in overweight and obese children and adolescents: association with obesity-related inflammation and oxidative stress. Adv Clin Exp Med. 2013;22(2):229-36. [Link]
25. Abd El Hamid ER, Abdel-Shaheed AA, Sabry RN, Youness ER, Shady MMA, Megawer AS, et al. Serum levels of monocyte chemoattractant protein-1, interlukin-6, and paraoxonase-1 in childhood obesity. J Arab Soc Med Res. 2015;10(1):27-31. [Link] [DOI:10.4103/1687-4293.159371]
26. Cervellati C, Bonaccorsi G, Trentini A, Valacchi G, Sanz JM, Squerzanti M, et al. Paraoxonase, arylesterase and lactonase activities of paraoxonase-1 (PON1) in obese and severely obese women. Scand J Clin Lab Invest. 2018;78(1-2):18-24. [Link] [DOI:10.1080/00365513.2017.1405274]
27. Kumon Y, Suehiro T, Ikeda Y, Hashimoto K. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1β and tumor necrosis factor-α, but is upregulated by interleukin-6. Life Sci. 2003;73(22):2807-15. [Link] [DOI:10.1016/S0024-3205(03)00704-5]
28. Cheng CC, Hsueh CM, Chen CY, Chen TH, Hsu SL. Interleukin-6 upregulates paraoxonase 1 gene expression via an AKT/NF-κB-dependent pathway. Biochem Biophys Res Commun. 2013;437(1):55-61. [LinkVV] [DOI:10.1016/j.bbrc.2013.06.034]
29. Meisinger C, Freuer D, Bub A, Linseisen J. Association between inflammatory markers and serum paraoxonase and arylesterase activities in the general population: a cross-sectional study. Lipids Health Dis. 2021;20(81):1-10. [V] [DOI:10.1186/s12944-021-01508-7]
30. Bełtowski J, Wójcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis. 2003;170(1):21-9. [Link] [DOI:10.1016/S0021-9150(03)00236-3]
31. Wu B, Fukuo K, Suzuki K, Yoshino G, Kazumi T. Relationships of systemic oxidative stress to body fat distribution, adipokines and inflammatory markers in healthy middle-aged women. Endocr J. 2009;56(6):773-82. [Link] [DOI:10.1507/endocrj.K08E-332]
32. Ruhe RC, McDonald RB. Use of antioxidant nutrients in the prevention and treatment of type 2 diabetes. J Am Coll Nutr. 2001;20(5 Suppl):363S-9S. [Link] [DOI:10.1080/07315724.2001.10719169]
33. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2005;90(3):1728-33. [Link] [DOI:10.1210/jc.2004-0486]
34. Mantovani RM, Rios DR, Moura LC, Oliveira JM, Carvalho FF, Cunha SB, et al. Childhood obesity: evidence of an association between plasminogen activator inhibitor-1 levels and visceral adiposity. J Pediatr Endocrinol Metab. 2011;24(5-6):361-7. [Link] [DOI:10.1515/jpem.2011.015]
35. Hassanin AAM, Elhusien AKA, Osman AM. Does obesity affect the plasma level of Plasminogen Activator Inhibitor-1? And does CO2 pneumoperitoneum affect it? Egyp J Anaesth. 2013;29(3):203-6. [LinkVV] [DOI:10.1016/j.egja.2013.02.007]
36. Somodi S, Seres I, Lőrincz H, Harangi M, Fülöp P, Paragh G. Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects. Int J Endocrinol. 2018;2018:9596054.. [Link] [DOI:10.1155/2018/9596054]
37. Mira MF, Anwar GM, Sarry EL-Din AM, Megahed SM. Assessment of plasminogen activator inhibitor-1 in obese Egyptian children. Egyp Pediatr Assoc Gazette. 2020;68(1):1-6. [Link] [DOI:10.1186/s43054-019-0012-8]
38. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404. [Link] [DOI:10.1152/physrev.00033.2011]
39. Jankun J, Al-Senaidy A, Skrzypczak-Jankun E. Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? Int J Mol Med. 2012;29(1):3-11. [Link] [DOI:10.3892/ijmm.2011.810]
40. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875-80. [Link] [DOI:10.1038/nature05487]
41. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2005;25(10):2043-53. [Link] [DOI:10.1161/01.ATV.0000181762.31694.da]
42. Kishore P, Li W, Tonelli J, Lee DE, Koppaka S, Zhang K, et al. Adipocyte-derived factors potentiate nutrient-induced production of plasminogen activator inhibitor-1 by macrophages. Sci Transl Med. 2010;2(20):20ra15. [Link] [DOI:10.1126/scitranslmed.3000292]
43. Tumova E, Sun W, Jones PH, Vrablik M, Ballantyne CM, Hoogeveen RC. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013;2013:729515. [Link] [DOI:10.1155/2013/729515]
44. Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab. 2013;98(10):E1610-9. [Link] [DOI:10.1210/jc.2013-2038]
45. Shulkina SG, Smirnova EN, Yudin MI, Osadchuk MA, Trushin MV. Adipocytokines in metabolically healthy obesity. Italian J Med. 2019;13(3):169-75. [Link] [DOI:10.4081/itjm.2019.1075]
46. Unic A, Derek L, Hodak N, Marijancevic D, Ceprnja M, Serdar T, et al. Endothelins-clinical perspectives. Biochem Med. 2011;21(3):231-42. [Link] [DOI:10.11613/BM.2011.032]
47. Ahmed NSM, Sulaiman SR. Correlation between Endothelin-1 and oxidative stress in apparently healthy obese men. Zanco J Med Sci. 2016;20(3):1513-9. [Link] [DOI:10.15218/zjms.2016.0052]
48. Sutton G, Pugh D, Dhaun N. Developments in the role of endothelin-1 in atherosclerosis: a potential therapeutic target? Am J Hypertens. 2019;32(9):813-5. [Link] [DOI:10.1093/ajh/hpz091]
49. Weil BR, Westby CM, Van Guilder GP, Greiner JJ, Stauffer BL, DeSouza CA. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiology Heart Circ Physiol. 2011;301(3):H689-95. [Link] [DOI:10.1152/ajpheart.00206.2011]
50. Eriksson AKS, Van Harmelen V, Stenson BM, Åström G, Wåhlén K, Laurencikiene J, et al. Endothelin-1 stimulates human adipocyte lipolysis through the ETA receptor. Int J Obes. 2009;33(1):67-74. [Link] [DOI:10.1038/ijo.2008.212]
51. Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA. Molecular regulation of the endothelin-1 gene by hypoxia: contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP. J Biol Chem. 2001;276(16):12645-53. [Link] [DOI:10.1074/jbc.M011344200]
52. Jenkins HN, Rivera‐Gonzalez O, Gibert Y, Speed JS. Endothelin‐1 in the pathophysiology of obesity and insulin resistance. Obes Rev. 2020;21(12):1-9. [Link] [DOI:10.1111/obr.13086]